Overexpression of RAB34 correlates with poor prognosis and tumor progression in hepatocellular carcinoma

Wu,Jianwu; Lu,Yijie; Qin,Ancheng; Qiao,Zhiming; Jiang,Xinwei

doi:10.3892/or.2017.5957

Overexpression of RAB34 correlates with poor prognosis and tumor progression in hepatocellular carcinoma

Authors:
- Jianwu Wu
- Yijie Lu
- Ancheng Qin
- Zhiming Qiao
- Xinwei Jiang
View Affiliations

Affiliations: Department of General Surgery, Nanjing Medical University, Affiliated Suzhou Hospital, Gusu, Suzhou, Jiangsu 215000, P.R. China
Published online on: September 18, 2017 https://doi.org/10.3892/or.2017.5957
Pages: 2967-2974

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

RAB34, a protein belonging to the RAB family, is involved in protein transport, repositioning of lysosomes and activation of micropinocytosis. However, few studies have reported its function in human epithelial cancers. Immunohistochemistry (IHC) and western blotting were used to detect expression of RAB34 at the tissue and cell levels. Cell Counting Kit-8 (CCK-8), EDU assay and flow cytometry were used for analyzing cell proliferation. Transwell and scratch wound healing assays were used for assessing cell migration ability. Western blotting was used for detecting expression of E-cadherin and N-cadherin. In the present study, we found that both DNA copy and protein level of RAB34 were upregulating in human hepatocellular carcinoma (HCC) tissues when compared with that in adjacent tissues. Analysis of the correlation between RAB34 expression and clinicopathological features showed that patients with overexpression of RAB34 consistently had large tumor size, vessel invasion and poor tumor grade. Furthermore, overall survival analysis showed that patients with upregulated expression of RAB34 were associated with poor prognosis. Moreover, cell function experiments showed that suppression of RAB34 led to a lower proliferation rate and migration ability. In addition, this phenomenon may be attributed to cell cycle phase G1 arrest and mesenchymal-epithelial transition under condition of RAB34 suppression. The present study demonstrated that RAB34 plays an important role in the initiation and progression of HCC. Our results suggest a new therapeutic target for the clinical treatment of HCC.

View Figures

View References

1	Finn RS: Current and future treatment strategies for patients with advanced hepatocellular carcinoma: Role of mTOR inhibition. Liver Cancer. 1:247–256. 2012. View Article : Google Scholar : PubMed/NCBI
2	Forner A, Gilabert M, Bruix J and Raoul JL: Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 11:525–535. 2014. View Article : Google Scholar : PubMed/NCBI
3	Galmiche A, Chauffert B and Barbare JC: New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma. Cancer Lett. 346:159–162. 2014. View Article : Google Scholar : PubMed/NCBI
4	Wang T and Hong W: Interorganellar regulation of lysosome positioning by the Golgi apparatus through Rab34 interaction with Rab-interacting lysosomal protein. Mol Biol Cell. 13:4317–4332. 2002. View Article : Google Scholar : PubMed/NCBI
5	Wang T, Wong KK and Hong W: A unique region of RILP distinguishes it from its related proteins in its regulation of lysosomal morphology and interaction with Rab7 and Rab34. Mol Biol Cell. 15:815–826. 2004. View Article : Google Scholar : PubMed/NCBI
6	Wang T and Hong W: Assay and functional properties of Rab34 interaction with RILP in lysosome morphogenesisMethods in Enzymology. Academic Press; New York, NY: pp. 675–687. 2005, View Article : Google Scholar : PubMed/NCBI
7	Starling GP, Yip YY, Sanger A, Morton PE, Eden ER and Dodding MP: Folliculin directs the formation of a Rab34-RILP complex to control the nutrient-dependent dynamic distribution of lysosomes. EMBO Rep. 17:823–841. 2016. View Article : Google Scholar : PubMed/NCBI
8	Speight P and Silverman M: Diacylglycerol-activated Hmunc13 serves as an effector of the GTPase Rab34. Traffic. 6:858–865. 2005. View Article : Google Scholar : PubMed/NCBI
9	Alloatti A, Kotsias F, Pauwels AM, Carpier JM, Jouve M, Timmerman E, Pace L, Vargas P, Maurin M, Gehrmann U, et al: Toll-like receptor 4 engagement on dendritic cells restrains phago-lysosome fusion and promotes cross-presentation of antigens. Immunity. 43:1087–1100. 2015. View Article : Google Scholar : PubMed/NCBI
10	Kasmapour B, Gronow A, Bleck CK, Hong W and Gutierrez MG: Size-dependent mechanism of cargo sorting during lysosome-phagosome fusion is controlled by Rab34. Proc Natl Acad Sci USA. 109:pp. 20485–20490. 2012; View Article : Google Scholar : PubMed/NCBI
11	Wang HJ, Gao Y, Chen L, Li YL and Jiang CL: RAB34 was a progression- and prognosis-associated biomarker in gliomas. Tumour Biol. 36:1573–1578. 2015. View Article : Google Scholar : PubMed/NCBI
12	Salic A and Mitchison TJ: A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc Natl Acad Sci USA. 105:pp. 2415–2420. 2008; View Article : Google Scholar : PubMed/NCBI
13	Goitre L: The Ras superfamily of small GTPases: The unlocked secretsRas Signaling: Methods and Protocols. Trabalzini L and Retta SF: Humana Press; Totowa, NJ: pp. 1–18. 2014, View Article : Google Scholar
14	Wennerberg K, Rossman KL and Der CJ: The Ras superfamily at a glance. J Cell Sci. 118:843–846. 2005. View Article : Google Scholar : PubMed/NCBI
15	Chan AM and Weber T: A putative link between exocytosis and tumor development. Cancer Cell. 2:427–428. 2002. View Article : Google Scholar : PubMed/NCBI
16	Wright PK: Targeting vesicle trafficking: An important approach to cancer chemotherapy. Recent Patents Anticancer Drug Discov. 3:137–147. 2008. View Article : Google Scholar
17	Chia WJ and Tang BL: Emerging roles for Rab family GTPases in human cancer. Biochim Biophys Acta. 1795:110–116. 2009.PubMed/NCBI
18	Tong M, Chan KW, Bao JY, Wong KY, Chen JN, Kwan PS, Tang KH, Fu L, Qin YR, Lok S, et al: Rab25 is a tumor suppressor gene with antiangiogenic and anti-invasive activities in esophageal squamous cell carcinoma. Cancer Res. 72:6024–6035. 2012. View Article : Google Scholar : PubMed/NCBI
19	Dong WW, Mou Q, Chen J, Cui JT, Li WM and Xiao WH: Differential expression of Rab27A/B correlates with clinical outcome in hepatocellular carcinoma. World J Gastroenterol. 18:1806–1813. 2012. View Article : Google Scholar : PubMed/NCBI
20	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
21	Murray AW: Recycling the cell cycle: Cyclins revisited. Cell. 116:221–234. 2004. View Article : Google Scholar : PubMed/NCBI
22	Sears RC and Nevins JR: Signaling networks that link cell proliferation and cell fate. J Biol Chem. 277:11617–11620. 2002. View Article : Google Scholar : PubMed/NCBI
23	Nieto MA and Cano A: The epithelial-mesenchymal transition under control: Global programs to regulate epithelial plasticity. Semin Cancer Biol. 22:361–368. 2012. View Article : Google Scholar : PubMed/NCBI
24	Guarino M, Rubino B and Ballabio G: The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 39:305–318. 2007. View Article : Google Scholar : PubMed/NCBI
25	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI